Diseases, Conditions, Syndromes

Hydroxyurea may reverse sickle cell-related heart abnormalities

Heart abnormalities are common complications of sickle cell anemia (SCA) that can contribute to severe disease symptoms and even death. A study published today in the journal Blood Advances is the first to find that hydroxyurea ...

Diseases, Conditions, Syndromes

Sickle cell anemia treatment does not increase malaria risk in Africa

The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study published online today in Blood, a Journal of the ...

page 1 from 3

Hydroxycarbamide

Hydroxycarbamide (INN) or hydroxyurea (brand names include Hydrea and Droxia) is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.

This text uses material from Wikipedia, licensed under CC BY-SA